JPRN-UMIN000027340已完成未知
Estimation of efficacy of glabridin to reduce visceral fat area - Effect of glabridin on visceral fat area
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Subjects under medication. 2.Subjects taking medicine and food that might impact the outcome measures. 3.Patients with serious disease such as renal disease, heart disease, respiratory illness, internal secretion disease, diabetes 4.Subjects who has allergy to experimental diet. 5.Subjects who are under treatment for or have a history of drug addiction and/or alcoholism. 6.Subjects who has metal in the body wherethe CT scanning measurement position 7.Susbjects who has implantable meicalequipments such as pacemaker and defibrillator. 8.Subjects who has Claustrophobia. 9.Shift workers, late-night workers 10.Subjects who have been diagnosed with familial. 11.Subjects who are planning to become pregnant during the study or are pregnant or lactating. 12.Subjects who are participating or planning to participate in other clinical studies to examine effects of food, medicine or cosmetics. 13.Subjects who are judged as unsuitable for the study by the investigator for other reasons.
研究者
相似试验
已完成
不适用
Clinical study on the effects of vildagliptin on glucose and lipid profiles in patients type 2 diabetes mellitusJPRN-UMIN000010451Department of Cardiology100
已完成
4 期
Study for the effects of vildagriptin in combination with metformin on vascular endothelial function and systemic metabolism in patients with type 2 diabetes -multicenter, prospective, randomized, open-label, parallel group comparisontype 2 diabetes mellitusJPRN-UMIN000011063Study group for the treatment of type 2 diabetes in Sapporo110
已完成
3 期
Effects of oral glibenclamide in patients with traumatic brain injuryBrain contusion.Focal brain injuryIRCT2014121720353N1Vice Chancellor of Research, Shiraz University of Medical Sciences104
Unknown
3 期
Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes MellitusInsulin Dependent DiabetesJuvenile Onset Diabetes MellitusAutoimmune DiabetesType 1 DiabetesNCT01559025Federal University of São Paulo44
未知
3 期
To assess the efficacy and safety of vildagliptin as add-on therapy to sulfonylurea in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapyType 2 DiabetesJPRN-jRCT2080220244ovartis Pharma K.K.200